Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-Naïve patients with rheumatoid arthritis: A single-center prospective study at 1 year (the Keio First-Bio Cohort study)

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Izumi, Keisuke ^a,b   Kaneko, Yuko ^a   Hashizume, Misato ^c   Yoshimoto, Keiko ^a   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; OSTEONECTIN; OSTEOPONTIN; PREDNISOLONE; RHEUMATOID FACTOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; CYTOKINE; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DISEASE DURATION; DRUG USE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION;

EID: 84956895124     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145468     Document Type: Article

References (17)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N EnglJ Med. 2001; 344:907-16. PMID: 11259725
2. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007; 7:429-42. PMID: 17525752
3. Arnett FC, Edworthy SM, Bloch D.A., McShane DJ, Fries JF, Cooper NS, et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31:315-24. PMID: 3358796
4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69:1580-8. doi: 10.1136/ard.2010.138461 PMID: 20699241
5. Todd DJ, Knowlton N, Amato M., Frank MB, Schur PH, Izmailova ES, et al Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. Arthritis Rheum. 2011; 63:894-903. doi: 10.1002/art.30213 PMID: 21305505
6. Izumi K, Kaneko Y, Yasuoka H., Seta N, Kameda H, Kuwana M., et al. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: A single-center retrospective cohort study (KEIO-TCZ study) at week 52. Mod Rheumatol. 2015 Jan; 25:31-7. doi: 10.3109/14397595.2014.897793 PMID: 24684408
7. Kawashiri SY, Kawakami A, Iwamoto N., Fujikawa K, Aramaki T, Tamai M., et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol. 2011; 21:370-4. doi: 10.1007/s10165-010-0409-0 PMID: 21240618
8. Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2013; 43:9-17. doi: 10.1016/j.semarthrit.2012.11.007 PMID: 23290690
9. Nishina N, Kikuchi J, Hashizume M., Yoshimoto K, Kameda H, Takeuchi T. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis. 2014; 73:945-7. doi: 10.1136/annrheumdis-2013-204137 PMID: 24336338
10. Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, et al. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol. 2013; 23:977-85. doi: 10.1007/s10165-012-0782-y PMID: 23099471
11. Katchamart W, Johnson S, Lin H.J., Phumethum V., Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken). 2010; 62:1128-43.
12. Xu G, Nie H, Li N., Zheng W, Zhang D, Feng G., et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest. 2005; 115:1060-7. PMID: 15761492
13. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol. 2002; 29:2061-7. PMID: 12375312
14. Gazal S, Sacre K, Allanore Y., Teruel M, Goodall AH, Tohma S, et al. Identification of secreted phospho-protein 1 gene as a new rheumatoid arthritis susceptibility gene. Ann Rheum Dis. 2015; 74:e19. doi: 10.1136/annrheumdis-2013-204581 PMID: 24448344
15. Take Y, Nakata K, Hashimoto J., Tsuboi H, Nishimoto N, Ochi T, et al. Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6. Arthritis Rheum. 2009; 60:3591-601. doi: 10.1002/art.25020 PMID: 19950274
16. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA. 2002; 99:4556-61. PMID: 11930008
17. Hashizume M, Hayakawa N, Suzuki M., Mihara M. IL-6/sIL-6R trans-signalling, butnotTNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int. 2009; 29:1449-54. doi: 10.1007/s00296-009-0885-8 PMID: 19277666